Transcriptomic profiling performed in bladder carcinomas collected from Neodurvarib clinical trial (NCT03534492)

RNASeq profiling of bladder carcinomas from different histologies (urothelial carcinomas or squamous cell carcinomas) which were collected at different moments of the Neodurvarib-related clinical procedure (pretreatment ("SCR") or post-treatment ("Q")). The main goals of the screening were 1) to define potential predictive/prognostic biomarkers (genes or molecular pathways) through the comparison of diagnostic samples ("SCR") according to the clinical response observed in the patients under study; ii) to evaluate the molecular changes observed in the tumors under study by comparing the profiles of diagnostic samples ("SCR") versus cystectomies ("Q"), which would be a direct consequence of the neoadjuvant therapy used in this clinical trial. Diagnostic samples were collected from TURBT specimens ("SCR"), just before the start of neoadyuvancy treatment with both Olaparib (PARPi, Astra Zeneca) and Durvalumab (PDL1 inhibitor, Astra Zeneca). On the other hand, samples named with "Q" indicated tumoral tissues collected from surgical procedure (cystectomy). Samples analyzed included tissues from 19 different patients, either from the TURBT, cystectomy or both surgical procedures. The arabic numbers included in the sample title indicate the id of the patient under study. No technical or biological replicates from such specimens were included in the RNA sequencing approach.